Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5168254 | 1.00 | MCL1 (0.50) | MCL1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL762892 | 1.00 | MCL1 (0.50) | MCL1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL13710832 | 0.88 | ALDH1A1 (0.56) | MAPTALDH1A1TSHRPOLBLMNA | |
| SCHEMBL6683531 | 0.84 | ALDH1A1 (0.52) | MCL1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL292450 | 0.83 | MEN1 (0.47) | MCL1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL292451 | 0.83 | MEN1 (0.47) | MCL1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL13710834 | 0.82 | ALDH1A1 (0.50) | MAPTALDH1A1TSHRPOLBLMNA | |
| SCHEMBL13969038 | 0.82 | ALDH1A1 (0.50) | MAPTALDH1A1TSHRPOLBLMNA | |
| SCHEMBL13710861 | 0.82 | ALDH1A1 (0.50) | MAPTALDH1A1TSHRPOLBLMNA | |
| SCHEMBL13908793 | 0.80 | GABRA1 (0.53) | MAPTALDH1A1TSHRPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110020251-A1 | Ultraviolet-Absorbing Compounds | AVOCA LLC | 2011-01-27 | — | — | US | claimed |
| EP-1252203-B1 | METHOD FOR PRODUCING A POLYMERIC CONVERSION PRODUCT | BASF AG (DE) | 2004-03-17 | — | — | EP | claimed |
| CN-113813792-B | Process for producing hypophosphorous acid by bipolar membrane electrodialysis | 湖北吉星化工集团有限责任公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-113813792-A | Process for producing hypophosphorous acid by bipolar membrane electrodialysis | 湖北吉星化工集团有限责任公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-105742638-B | Adhesive for rechargeable lithium ion battery, separator for rechargeable lithium ion battery, and rechargeable lithium ion battery | 三星SDI株式会社 | 2020-08-18 | — | — | CN | disclosed |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9717730-B2 | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | GENENTECH, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170157124-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9610289-B2 | Combinations of AKT inhibitor compounds and erlotinib, and methods of use | GENENTECH, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160228440-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| EP-1203761-A2 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001044327-A2 | METHOD FOR PRODUCING A POLYMERIC CONVERSION PRODUCT | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-21 | — | — | WO | disclosed |
| US-6211244-B1 | AROMATIC AMINES FOR COMPLEXING CALCIUM | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| WO-1996012697-A9 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMA INC (US) | 2000-08-24 | — | — | WO | disclosed |
| US-5859110-A | Method of decreasing bleed from organic-based formulations and anti-bleed compostitions | JOHNSON MATTHEY, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0787122-A2 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012697-A2 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| EP-0546115-A1 | PEPTIDES CONTAINING AMINO-POLYOLS AS TRANSITION-STATE MIMICS | THE UPJOHN COMPANY (US) | 1993-06-16 | — | — | EP | disclosed |
| US-4576793-A | MULTILAYER, POROSITY, SPREADING, UNSATURATED ACID COPOLYMEWR | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1986-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157124-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | AKT1, AKT2, MTOR | MCL1 185/4885RAB9A 789/4885MAPT 2521/4885 |
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | MCL1 276/4885RAB9A 1697/4885MAPT 3730/4885 |
| US-20110020251-A1 | Ultraviolet-Absorbing Compounds | UFM1, UHRF1, CUTA | MCL1 3537/4885RAB9A 4431/4885MAPT 322/4885 |
| US-20160228440-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | AKT1, AKT2, MTOR | MCL1 185/4885RAB9A 789/4885MAPT 2521/4885 |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | MCL1 257/4885RAB9A 1810/4885MAPT 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.